#United States #San Francisco #Hamamatsu #Biocare Medical #MoxiePlex

Biocare Medical and Hamamatsu Join Forces for Spatial Biology Innovation

In a groundbreaking announcement made on October 30, 2025, Biocare Medical and Hamamatsu Corporation revealed their strategic collaboration aimed at advancing the field of spatial biology. This partnership holds significant promise for researchers in the realms of immunohistochemistry and digital imaging technology.

A New Era in Spatial Biology

Biocare Medical, recognized globally for its advancements in immunohistochemistry instruments and reagents, teams up with Hamamatsu, a leader in imaging technologies, to enhance the burgeoning field of spatial biology. The partnership will see Biocare offering Hamamatsu's state-of-the-art MoxiePlex™ multi-spectral imaging system in conjunction with its advanced ONCORE Pro X™ automated staining instrument. This integration is intended to streamline the workflow involved in multiplex immunofluorescence and IHC staining, culminating in high-resolution digital imaging.

The coordinated approach promises to elevate the precision and efficiency of research endeavors across pharmaceutical and biotechnology firms, academic institutions, and contract research organizations (CROs). With these technologies combined, researchers will be empowered to generate high-quality, digital-ready data faster, enhancing discovery in crucial areas such as cancer research and drug development.

Expert Opinions

David Anderson, the VP of Strategic Partnerships at Biocare, expressed optimism regarding this collaboration: "This collaboration combines Biocare's extensive staining expertise with Hamamatsu's innovative digital imaging technology to formulate a comprehensive solution for spatial biology. Together, we are facilitating faster, high-quality data generation for researchers involved in cancer diagnostics and treatment development."

On the other hand, James Butler, VP of Marketing at Hamamatsu, shared similar sentiments, stating, "Working with Biocare enables us to broaden the impact of MoxiePlex by integrating it with a well-established staining platform that excels in spatial biology assays. We are thrilled to collaborate in delivering a scalable solution that empowers scientists and clinicians to further the goals of precision medicine."

Strengthening Market Position

This alliance further solidifies Biocare's commitment to fostering collaborations within the spatial biology ecosystem, enhancing its existing partnerships with leading research and technology providers. For Hamamatsu, the accord enhances its footprint in the immunohistochemistry and spatial biology sectors through Biocare’s well-established stain platforms and vast global network.

By joining forces, Biocare and Hamamatsu set a new benchmark for multiplex immunofluorescence research workflows, delivering a solution that is not only reproducible and scalable but also fully integrated. This initiative represents a pivotal advancement for applications in spatial biology, potentially transforming how research is conducted.

About the Companies

Biocare Medical stands at the forefront of oncology research through its pioneering immunohistochemistry and molecular pathology solutions. The company is dedicated to offering automated instruments, top-notch reagents, and digital solutions to advance cancer diagnostics globally.

Hamamatsu Photonics, renowned for its innovative photonics technology, specializes in cutting-edge imaging and optical systems. The MoxiePlex™, designed for research purposes, progresses spatial proteomics research, particularly in immuno-oncology and further applications in pathology.

In conclusion, the collaboration between Biocare Medical and Hamamatsu Corporation is poised to propel advancements in the spatial biology landscape, ultimately benefiting researchers and patients alike in their quest for precision medicine solutions.